Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2007
Date:2/13/2008

3,958 -

Deferred income tax - long term 75 -

Deferred revenue 4,607 3,667

Deferred rent 10 128

Deferred compensation plan liabilities 1,893 1,211

Commitments and contingencies

Stockholders' equity:

Preferred stock, $.0001 par value per share,

20,000,000 shares authorized,

none issued and outstanding - -

Common stock, $.0001 par value per share;

200,000,000 shares authorized,

53,916,298 and 52,233,656 shares issued and

outstanding at December 31, 2007 and

December 31, 2006, respectively 5 5

Additional paid-in capital 415,229 334,184

Accumulated other comprehensive income (loss) 1,604 (5)

Retained earnings 321,202 236,024

Total stockholders' equity 738,040 570,208

Total liabilities and stockholders' equity $789,053 $623,839

Gen-Probe Incorporated

Consolidated Statements of Income

(In thousands, except per share data)

Three Months Ended Twelve Months Ended

December 31, December 31,

2007 2006 2007 2006

Revenues:

Product sales $92,426 $85,496 $370,877 $325,307

Collaborative research revenue 5,380 1,194 16,619 15,937

Royalty and license revenue 1,143 4,369 15,518 13,520

Total revenues 98,949 91,059 403,014 354,764

Operating expenses:

Cost of product s
'/>"/>

SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Carl Hull Named President and Chief Operating Officer of Gen-Probe
2. Gen-Probe Announces Webcast of Fourth Quarter and Full Year 2007 Earnings Conference Call
3. Gen-Probe to Webcast Three Upcoming Presentations
4. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
5. Gen-Probe to Webcast Presentation at Bank of Americas 37th Annual Investment Conference
6. Imagenetix Inc. Reports Third Fiscal Quarter Results
7. China-Biotics, Inc. Reports Third Quarter 2008 Financial Results
8. Maxygen Reports Fourth Quarter and Year End 2007 Financial Results
9. Cynosure Reports Record Revenues and Net Income for the Fourth Quarter of 2007
10. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
11. Schering-Plough Reports Financial Results for 2007 Fourth Quarter, Full Year
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Biology News(10 mins):U. of I. business instructional facility achieves top 'green' standard 2U. of I. business instructional facility achieves top 'green' standard 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 2Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 3Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 4Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 5Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 6Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 7Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 8Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 9Leibniz Prize 2010: 10 winners receive honor, prize money and 'idyllic freedom' 10Superior offspring without genetic modification 2Many Doctors Still Dont Disclose Consulting Fees 59090 1Many Doctors Still Dont Disclose Consulting Fees 59090 2Many Doctors Still Dont Disclose Consulting Fees 59090 3National Health Care Reformers Should Pay Attention to Lawsuit Alleging that Nations Largest Insurer Routinely Denies Liver Transplants 59086 1National Health Care Reformers Should Pay Attention to Lawsuit Alleging that Nations Largest Insurer Routinely Denies Liver Transplants 59086 2Coverall Named Among 50 Top Franchises for Minorities for Third Consecutive Year 59081 1Coverall Named Among 50 Top Franchises for Minorities for Third Consecutive Year 59081 2